Navigation Links
Visikol Machine Learning Digital Pathology Services for Drug Discovery

Since the inception of the microscope, researchers and clinicians have characterized tissues through the visualization of histopathology slides by eye wherein key features are used for classification. While this type of human driven approach is the gold standard for diagnosis and research, it is highly limited in that it is a qualitative and low-throughput approach where only a few features are used for characterization from a small region of interest.

This field of pathology is ripe for disruption as advances in computer vision and data processing now allow for thousands of tissues to be analyzed per day by a computer that evaluates not only a few features, but thousands of features from an entire slide in a quantitative manner. “The ability to evaluate large numbers of features from a single slide means that we can start to identify unique biomarkers such as the circularity of nuclei being correlated to a specific disease phenotype. Computer vision provides the ability to find novel biomarkers that a human could never even consider” described Visikol Chief Science Officer Dr. Thomas Villani. Traditionally, the way pathologists interpret slides is to look for tissue specific features that they have learned from their studies and practical experience. The major benefit of a computer-based approach is that instead of relying on a pathologist’s memory and training, a slide can be compared to vast archives of digital slides and their corresponding metadata.

As a pre-clinical drug discovery contract research organization, Visikol has always been focused on transforming tissues and cells into quantitative insights for clients. Initially, Visikol focused predominantly on 3D tissue imaging through the use of tissue clearing, but has since expanded into the digital pathology, high content screening and 3D cell culture assay fields. “We originally developed digital pathology tools for use with very large three-dimensional data sets that we were generating from tissues using light sheet or confocal microscopy. After using these approaches for a wide range of applications, we realized that our digital pathology approach could also be used in a two-dimensional context with traditional 2D H&E, IHC and FISH slides” explained Visikol Chief Executive Officer Dr. Michael Johnson.

In 2018, Visikol began partnering with pharmaceutical companies to offer its 3Screen™ digital pathology tools for use in their drug discovery efforts. Visikol partners with pharmaceutical companies wherein they send boxes of glass microscope slides or hard drives of scanned slides for analysis by Visikol who transforms these raw data sets into actionable insights. “We see digital pathology as a transformational change for drug discovery as it allows pharmaceutical companies to acquire better and more accurate data from tissues while leveraging huge data sets to identify novel correlations or biomarkers. Ultimately, tissues are just data sets and by digitizing this data we can now make use of advanced analysis techniques that allow us to ask and answer more complex research questions” described Dr. Johnson.

In offering digital pathology services to pharmaceutical companies, Visikol is agnostic about the type of tissue it is working with and focuses entirely on how best to answer a client’s research question. The projects that Visikol works on for clients range from simple area or scoring quantification to developing regulated machine learning digital pathology software for use with patients. Recently, Visikol announced its collaboration with Enzyvant Therapeutics through which it leveraged its 3Screen™ digital pathology services to develop a digital pathology quality control assay to support the introduction of RVT-802 (i.e. transplantable thymus tissue). Such machine learning projects require that clients have detailed histological databases but enable for an in depth understanding of what specific tissue properties effect a disease phenotype. Regardless of the project, Visikol works closely with clients to understand their needs and builds a customized approach to address their research question and desired end-points.

About Visikol
Visikol is a contract research organization that is focused on accelerating drug discovery through the transformation of tissues into actionable and quantitative insights. Visikol is comprised of experts in imaging, digital pathology, machine learning and advanced in vitro models. The company leverages this expertise along with a portfolio of proprietary imaging and image analysis technologies to offer pharmaceutical/biotech clients its 3Screen™ services which are comprised of 3D cell culture assays, digital pathology services, 3D tissue imaging services, high content screening and customized drug discovery solutions. Visikol partners closely with clients in drug discovery efforts and to assist them with using innovative assays for drug screening that are more rapid, reliable, and relevant for screening. In addition to this service offering, Visikol also sells various tissue clearing reagents and kits for researchers that are interested in adopting 3D tissue imaging into their own workflows. For more information about Visikol or its 3Screen™ services, please visit our website at

For additional assistance, journalists, investors and analysts may contact:
Dr. Michael Johnson
CEO and Co-Founder

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dr. Michael Johnson, CEO and Co-founder of Visikol, Invited to Speak with Governor Murphy on Behalf of the Science, Innovation, and Technology Commission Bill
2. Ribbon Cutting and Open House at Milwaukee Area Technical College on Oct. 17 to Spotlight New CNC Swiss Machinery and Expanded Instructional Capacity
3. Franz’s Gruff Adds “Time Machine” Feature for Temporal Graph Analytics
4. Microscan To Demonstrate Advancements in Barcode and Machine Vision Technology at AACC Clinical Lab Expo 2017
5. 2017 Foresight Fellows Announced in Molecular Machines, Space, Longevity, Artificial Intelligence
6. FireflySci Develops New Agilent Flow Cell Line for HPLC Machines
7. Wearable Tech + Digital Tech + NeuroTech NYC: Sensors - Data - AI - BCI - Machine Learning - VR/AR in health
8. Morris Midwest Will Hold an Open House and CNC Machine Tool Show in Maple Grove, Minnesota, May 11-12 for Manufacturers of Precision Machined Parts
9. Talon Innovations Corporation Acquires Vulcan Machine, Inc.
10. MachineShop Internet of Things (IoT) Platform Selected by Milwaukee Instruments to Power Its New Web-Enabled Water Monitoring Solution
11. Global PDT Machine Industry Report 2014
Post Your Comments:
(Date:2/28/2020)... (PRWEB) , ... February 26, 2020 , ... ... system combines a high-speed camera with a dedicated controller, thus simplifying setup, ... per second, the HS7 is the first of Fastec Imaging’s new HS Series ...
(Date:2/21/2020)... ... ... In a free session on Tuesday, March 10, 2020 at ... BS, MS, Vice President Rare, Orphan and Pediatric Diseases, and Rachael Young, Associate Director, ... patients, sites and sponsors. , When planning a rare disease clinical trial, drug developers ...
(Date:2/21/2020)... N.Y. (PRWEB) , ... February 20, 2020 , ... ... for ensuring supply chain transparency and reassuring consumers that what’s listed on an ... and trademarked ingredients, Nutrition21 has introduced this solution with the adoption of CertainT, ...
(Date:2/21/2020)... ... February 21, 2020 , ... Pharmaceutical manufacturers ... in order to adapt to new approaches like ‘Industry 4.0’ and continuous manufacturing, ... for personalized medicine and therapies. But with an industry with the world’s tightest ...
Breaking Biology Technology:
(Date:3/2/2020)... (PRWEB) , ... March 02, 2020 , ... Toronto-based clinical ... is soon opening its newest office location just 5 minutes south of Clarksburg on ... orchard on the property, called End of the Rainbow Orchard, and decided it would ...
(Date:3/2/2020)... SILVER SPRING, Md. (PRWEB) , ... March 02, 2020 , ... ... , a globally-recognized program co-founded by the Security Industry Association (SIA) and ... and the SIA Women in Security Forum . The recipients of this year’s ...
(Date:2/28/2020)... ... , ... Meridian Clinical Research , a leading investigative research network, is ... Best Clinical Trial Site. Meridian is also the largest member of Platinum Research ... nominations were the result of two voting rounds, and winners will be announced at ...
Breaking Biology News(10 mins):